170 related articles for article (PubMed ID: 33345803)
1. Inhibition of cholinesterases by safranin O: Integration of inhibition kinetics with molecular docking simulations.
Onder S; Sari S; Tacal O
Arch Biochem Biophys; 2021 Feb; 698():108728. PubMed ID: 33345803
[TBL] [Abstract][Full Text] [Related]
2. The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by methylene violet 3RAX.
Onder S; Biberoglu K; Tacal O
Chem Biol Interact; 2019 Dec; 314():108845. PubMed ID: 31593690
[TBL] [Abstract][Full Text] [Related]
3. Toluidine blue O is a potent inhibitor of human cholinesterases.
Biberoglu K; Tek MY; Ghasemi ST; Tacal O
Arch Biochem Biophys; 2016 Aug; 604():57-62. PubMed ID: 27296777
[TBL] [Abstract][Full Text] [Related]
4. Differences in active-site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase.
Saxena A; Redman AM; Jiang X; Lockridge O; Doctor BP
Chem Biol Interact; 1999 May; 119-120():61-9. PubMed ID: 10421439
[TBL] [Abstract][Full Text] [Related]
5. Azole derivatives inhibit wildtype butyrylcholinesterase and its common mutants.
Sari S; Önder S; Akkaya D; Sabuncuoğlu S; Zengin M; Barut B; Karakurt A
Drug Dev Res; 2023 Aug; 84(5):1018-1028. PubMed ID: 37154110
[TBL] [Abstract][Full Text] [Related]
6. Identification of New Chromenone Derivatives as Cholinesterase Inhibitors and Molecular Docking Studies.
Iqbal J; Abbasi MSA; Zaib S; Afridi S; Furtmann N; Bajorath J; Langer P
Med Chem; 2018; 14(8):809-817. PubMed ID: 29473519
[TBL] [Abstract][Full Text] [Related]
7. Aromatic amino-acid residues at the active and peripheral anionic sites control the binding of E2020 (Aricept) to cholinesterases.
Saxena A; Fedorko JM; Vinayaka CR; Medhekar R; Radić Z; Taylor P; Lockridge O; Doctor BP
Eur J Biochem; 2003 Nov; 270(22):4447-58. PubMed ID: 14622273
[TBL] [Abstract][Full Text] [Related]
8. Structural aspects of 4-aminoquinolines as reversible inhibitors of human acetylcholinesterase and butyrylcholinesterase.
Bosak A; Opsenica DM; Šinko G; Zlatar M; Kovarik Z
Chem Biol Interact; 2019 Aug; 308():101-109. PubMed ID: 31100281
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of acetylcholinesterase and butyrylcholinesterase by chlorpyrifos-oxon.
Amitai G; Moorad D; Adani R; Doctor BP
Biochem Pharmacol; 1998 Aug; 56(3):293-9. PubMed ID: 9744565
[TBL] [Abstract][Full Text] [Related]
10. Flavonols and 4-thioflavonols as potential acetylcholinesterase and butyrylcholinesterase inhibitors: Synthesis, structure-activity relationship and molecular docking studies.
Mughal EU; Sadiq A; Ashraf J; Zafar MN; Sumrra SH; Tariq R; Mumtaz A; Javid A; Khan BA; Ali A; Javed CO
Bioorg Chem; 2019 Oct; 91():103124. PubMed ID: 31319297
[TBL] [Abstract][Full Text] [Related]
11. Syntheses, cholinesterases inhibition, and molecular docking studies of pyrido[2,3-b]pyrazine derivatives.
Hameed A; Zehra ST; Shah SJ; Khan KM; Alharthy RD; Furtmann N; Bajorath J; Tahir MN; Iqbal J
Chem Biol Drug Des; 2015 Nov; 86(5):1115-20. PubMed ID: 25951978
[TBL] [Abstract][Full Text] [Related]
12. In silico, theoretical biointerface analysis and in vitro kinetic analysis of amine compounds interaction with acetylcholinesterase and butyrylcholinesterase.
Kandasamy S; Loganathan C; Sakayanathan P; Karthikeyan S; Stephen AD; Marimuthu DK; Ravichandran S; Sivalingam V; Thayumanavan P
Int J Biol Macromol; 2021 Aug; 185():750-760. PubMed ID: 34216669
[TBL] [Abstract][Full Text] [Related]
13. Molecular-docking-guided design and synthesis of new IAA-tacrine hybrids as multifunctional AChE/BChE inhibitors.
Cheng ZQ; Zhu KK; Zhang J; Song JL; Muehlmann LA; Jiang CS; Liu CL; Zhang H
Bioorg Chem; 2019 Mar; 83():277-288. PubMed ID: 30391700
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of two different cholinesterases by tacrine.
Ahmed M; Rocha JB; Corrêa M; Mazzanti CM; Zanin RF; Morsch AL; Morsch VM; Schetinger MR
Chem Biol Interact; 2006 Aug; 162(2):165-71. PubMed ID: 16860785
[TBL] [Abstract][Full Text] [Related]
15. Ionic liquid mediated synthesis of mono- and bis-spirooxindole-hexahydropyrrolidines as cholinesterase inhibitors and their molecular docking studies.
Kia Y; Osman H; Kumar RS; Basiri A; Murugaiyah V
Bioorg Med Chem; 2014 Feb; 22(4):1318-28. PubMed ID: 24461561
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of β-site amyloid precursor protein cleaving enzyme 1 and cholinesterases by pterosins via a specific structure-activity relationship with a strong BBB permeability.
Jannat S; Balupuri A; Ali MY; Hong SS; Choi CW; Choi YH; Ku JM; Kim WJ; Leem JY; Kim JE; Shrestha AC; Ham HN; Lee KH; Kim DM; Kang NS; Park GH
Exp Mol Med; 2019 Feb; 51(2):1-18. PubMed ID: 30755593
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and cholinesterase inhibitory activity study of new piperidone grafted spiropyrrolidines.
Basiri A; Abd Razik BM; Ezzat MO; Kia Y; Kumar RS; Almansour AI; Arumugam N; Murugaiyah V
Bioorg Chem; 2017 Dec; 75():210-216. PubMed ID: 28987876
[TBL] [Abstract][Full Text] [Related]
18. The kinetic and molecular docking analysis of interactions between three V-type nerve agents and four human cholinesterases.
Li K; Liu Y; Liu Y; Li Q; Guo L; Xie J
Chem Biol Interact; 2023 Feb; 372():110369. PubMed ID: 36708975
[TBL] [Abstract][Full Text] [Related]
19. Discovery of methoxy-naphthyl linked N-(1-benzylpiperidine) benzamide as a blood-brain permeable dual inhibitor of acetylcholinesterase and butyrylcholinesterase.
Abdullaha M; Nuthakki VK; Bharate SB
Eur J Med Chem; 2020 Dec; 207():112761. PubMed ID: 32942070
[TBL] [Abstract][Full Text] [Related]
20. Inhibition pathways of the potent organophosphate CBDP with cholinesterases revealed by X-ray crystallographic snapshots and mass spectrometry.
Carletti E; Colletier JP; Schopfer LM; Santoni G; Masson P; Lockridge O; Nachon F; Weik M
Chem Res Toxicol; 2013 Feb; 26(2):280-9. PubMed ID: 23339663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
